Patents by Inventor W. Michael Gallatin

W. Michael Gallatin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • THERAPIES FOR HEMATOLOGIC MALIGNANCIES
    Publication number: 20200368243
    Abstract: The invention provides methods that relate to a novel therapeutic strategy for the treatment of hematological malignancies and inflammatory diseases. In particular, the method comprises administering a compound of formula A, wherein R is H, halo, or C1-C6 alkyl; R? is C1-C6 alkyl; or a pharmaceutically acceptable salt thereof; and optionally a pharmaceutically acceptable excipient; and administering at least one additional therapeutic agent.
    Type: Application
    Filed: August 10, 2020
    Publication date: November 26, 2020
    Inventors: W. Michael GALLATIN, Roger G. ULRICH, Neill A. GIESE, Brian J. LANNUTTI, Langdon MILLER, Thomas M. JAHN
  • THERAPIES FOR HEMATOLOGIC MALIGNANCIES
    Publication number: 20190083498
    Abstract: The invention provides methods that relate to a novel therapeutic strategy for the treatment of hematological malignancies and inflammatory diseases. In particular, the method comprises administering a compound of formula A, wherein R is H, halo, or C1-C6 alkyl; R? is C1-C6 alkyl; or a pharmaceutically acceptable salt thereof; and optionally a pharmaceutically acceptable excipient; and administering at least one additional therapeutic agent.
    Type: Application
    Filed: November 13, 2018
    Publication date: March 21, 2019
    Inventors: W. Michael GALLATIN, Roger G. ULRICH, Neill A. GIESE, Brian LANNUTTI, Langdon MILLER, Thomas M. JAHN
  • Therapies for hematologic malignancies
    Patent number: 10154998
    Abstract: The invention provides methods that relate to a novel therapeutic strategy for the treatment of hematological malignancies and inflammatory diseases. In particular, the method comprises administering a compound of formula A, wherein R is H, halo, or C1-C6 alkyl; R? is C1-C6 alkyl; or a pharmaceutically acceptable salt thereof; and optionally a pharmaceutically acceptable excipient; and administering at least one additional therapeutic agent.
    Type: Grant
    Filed: September 27, 2016
    Date of Patent: December 18, 2018
    Assignee: Gilead Calistoga LLC
    Inventors: W. Michael Gallatin, Roger G. Ulrich, Neill A. Giese, Brian Lannutti, Langdon Miller, Thomas M. Jahn
  • COMBINATION THERAPIES FOR HEMATOLOGIC MALIGNANCIES
    Publication number: 20170119771
    Abstract: The invention provides methods that relate to a novel therapeutic strategy for the treatment of hematological malignancies and inflammatory diseases. In particular, the method comprises administration of a compound of formula A, wherein R is H, halo, or C1-C6 alkyl; R? is C1-C6 alkyl; or a pharmaceutically acceptable salt thereof; and optionally a pharmaceutically acceptable excipient; and one or more additional therapeutic agents optionally selected from the group consisting of bendamustine, rituximah, and ofatumumab.
    Type: Application
    Filed: June 30, 2016
    Publication date: May 4, 2017
    Inventors: W. Michael GALLATIN, Roger G. ULRICH, Neill A. GIESE, Brian LANNUTTI, Albert YU, Langdon MILLER, Thomas M. JAHN
  • THERAPIES FOR HEMATOLOGIC MALIGNANCIES
    Publication number: 20170112841
    Abstract: The invention provides methods that relate to a novel therapeutic strategy for the treatment of hematological malignancies and inflammatory diseases. In particular, the method comprises administering a compound of formula A, wherein R is H, halo, or C1-C6 alkyl; R? is C1-C6 alkyl; or a pharmaceutically acceptable salt thereof; and optionally a pharmaceutically acceptable excipient; and administering at least one additional therapeutic agent.
    Type: Application
    Filed: September 27, 2016
    Publication date: April 27, 2017
    Inventors: W. Michael GALLATIN, Roger G. ULRICH, Neill A. GIESE, Brian LANNUTTI, Langdon MILLER, Thomas M. JAHN
  • Therapies for hematologic malignancies
    Patent number: 9492449
    Abstract: The invention provides methods that relate to a novel therapeutic strategy for the treatment of hematological malignancies and inflammatory diseases. In particular, the method comprises administering a compound of formula A, wherein R is H, halo, or C1-C6 alkyl; R? is C1-C6 alkyl; or a pharmaceutically acceptable salt thereof; and optionally a pharmaceutically acceptable excipient; and administering at least one additional therapeutic agent.
    Type: Grant
    Filed: March 9, 2012
    Date of Patent: November 15, 2016
    Assignee: Gilead Calistoga LLC
    Inventors: W. Michael Gallatin, Roger G. Ulrich, Neill A. Giese, Brian Lannutti, Langdon Miller, Thomas M. Jahn
  • Therapies for hematologic malignancies
    Patent number: 9238070
    Abstract: The invention provides methods that relate to a novel therapeutic strategy for the treatment of hematological malignancies and inflammatory diseases. In particular, the method comprises administration of a compound of formula A, wherein R is H, halo, or C1-C6 alkyl; R? is C1-C6 alkyl; or a pharmaceutically acceptable salt thereof; and optionally a pharmaceutically acceptable excipient.
    Type: Grant
    Filed: February 7, 2013
    Date of Patent: January 19, 2016
    Assignee: Gilead Calistoga LLC
    Inventors: W. Michael Gallatin, Roger G. Ulrich, Neill A. Giese
  • COMBINATION THERAPIES FOR HEMATOLOGIC MALIGNANCIES
    Publication number: 20150196564
    Abstract: The invention provides methods that relate to a novel therapeutic strategy for the treatment of hematological malignancies and inflammatory diseases. In particular, the method comprises administration of a compound of formula A, wherein R is H, halo, or C1-C6 alkyl; R? is C1-C6 alkyl; or a pharmaceutically acceptable salt thereof; and optionally a pharmaceutically acceptable excipient; and one or more additional therapeutic agents optionally selected from the group consisting of bendamustine, rituximab, and ofatumumab.
    Type: Application
    Filed: January 16, 2015
    Publication date: July 16, 2015
    Inventors: W. Michael GALLATIN, Roger G. ULRICH, Neill A. GIESE, Brian LANNUTTI, Albert YU, Langdon MILLER, Thomas M. JAHN
  • THERAPIES FOR HEMATOLOGIC MALIGNANCIES
    Publication number: 20140323439
    Abstract: The invention provides methods that relate to a novel therapeutic strategy for the treatment of hematological malignancies and inflammatory diseases. In particular, the method comprises administration of a compound of formula A, wherein R is H, halo, or C1-C6 alkyl; R? is C1-C6 alkyl; or a pharmaceutically acceptable salt thereof; and optionally a pharmaceutically acceptable excipient.
    Type: Application
    Filed: July 3, 2014
    Publication date: October 30, 2014
    Inventors: W. Michael GALLATIN, Roger G. ULRICH, Neill A. GIESE
  • THERAPIES FOR HEMATOLOGIC MALIGNANCIES
    Publication number: 20130071323
    Abstract: The invention provides methods that relate to a novel therapeutic strategy for the treatment of hematological malignancies and inflammatory diseases. In particular, the method comprises administering a compound of formula A, wherein R is H, halo, or C1-C6 alkyl; R? is C1-C6 alkyl; or a pharmaceutically acceptable salt thereof; and optionally a pharmaceutically acceptable excipient; and administering at least one additional therapeutic agent.
    Type: Application
    Filed: March 9, 2012
    Publication date: March 21, 2013
    Applicant: Gilead Calistoga LLC
    Inventors: W. Michael Gallatin, Roger G. Ulrich, Neill A. Giese, Brian Lannutti, Langdon Miller, Thomas M. Jahn
  • COMBINATION THERAPIES FOR HEMATOLOGIC MALIGNANCIES
    Publication number: 20130064812
    Abstract: The invention provides methods that relate to a novel therapeutic strategy for the treatment of hematological malignancies and inflammatory diseases. In particular, the method comprises administration of a compound of formula A, wherein R is H, halo, or C1-C6 alkyl; R? is C1-C6 alkyl; or a pharmaceutically acceptable salt thereof; and optionally a pharmaceutically acceptable excipient; and one or more additional therapeutic agents optionally selected from the group consisting of bendamustine, rituximab, and ofatumumab.
    Type: Application
    Filed: March 9, 2012
    Publication date: March 14, 2013
    Applicant: Gilead Calistoga LLC
    Inventors: W. Michael GALLATIN, Roger G. Ulrich, Neill A. Giese, Brian Lannutti, Albert Yu, Langdon Miller, Thomas M. Jahn
  • THERAPIES FOR HEMATOLOGIC MALIGNANCIES
    Publication number: 20100202963
    Abstract: The invention provides methods that relate to a novel therapeutic strategy for the treatment of hematological malignancies and inflammatory diseases. In particular, the method comprises administration of a compound of formula A, wherein R is H, halo, or C1-C6 alkyl; R? is C1-C6 alkyl; or a pharmaceutically acceptable salt thereof; and optionally a pharmaceutically acceptable excipient.
    Type: Application
    Filed: November 13, 2009
    Publication date: August 12, 2010
    Inventors: W. Michael GALLATIN, Roger G. Ulrich, Neill A. Giese
  • I-CAM related protein
    Patent number: 6818743
    Abstract: DNA sequences encoding a novel human intercellular adhesion molecule polypeptide (designated “ICAM-R”) and variants thereof are disclosed along with methods and materials for production of the same by recombinant procedures. Antibodies substances specific for ICAM-R and variants thereof are also disclosed as useful in both the isolation of ICAM-R from natural cellular sources and the modulation of ligand/receptor binding reactions involving ICAM-R.
    Type: Grant
    Filed: September 28, 1994
    Date of Patent: November 16, 2004
    Assignee: ICOS Corporation
    Inventors: W. Michael Gallatin, Rosemay Vazeux
  • ICAM-related protein
    Publication number: 20030199423
    Abstract: DNA sequences encoding a novel human intercellular adhesion molecule polypeptide (designated “ICAM-R”) and variants thereof are disclosed along with methods and materials for production of the same by recombinant procedures. Binding molecules specific for ICAM-R and variants thereof are also disclosed as useful in both the isolation of ICAM-R from natural cellular sources and the modulation of ligand/receptor binding biological activities of ICAM-R.
    Type: Application
    Filed: June 5, 2002
    Publication date: October 23, 2003
    Inventors: W. Michael Gallatin, Rosemay Vazeux
  • Monoclonal antibodies specific for integrin &agr;-d subunit
    Patent number: 6620915
    Abstract: The present invention relates to monoclonal antibodies immunospecific for &agr;d integrin, and antibodies that compete with said antibodies for &agr;d binding.
    Type: Grant
    Filed: July 8, 1999
    Date of Patent: September 16, 2003
    Assignee: ICOS Corporation
    Inventors: W. Michael Gallatin, Monica Van der Vieren
  • Novel human beta2 integrin alpha subunit
    Publication number: 20030077278
    Abstract: Methods to inhibit inflammation and macrophage infiltration following spinal cord injury are disclosed along with methods to modulate TNF&agr; release from cells expressing &agr;d are disclosed.
    Type: Application
    Filed: June 26, 2001
    Publication date: April 24, 2003
    Applicant: ICOS Corporation
    Inventors: W. Michael Gallatin, Monica Van der Vieren
  • ICAM-4 materials and methods
    Publication number: 20030068659
    Abstract: Methods for quantitating concentration of circulating ICAM-4 in association with various neurodegenerative disorders are provided.
    Type: Application
    Filed: December 18, 2001
    Publication date: April 10, 2003
    Applicant: ICOS Corporation
    Inventors: Patrick D. Kilgannon, W. Michael Gallatin
  • Methods of inhibiting locomotor damage following spinal cord injury with &agr; D-specific antibodies
    Patent number: 6432404
    Abstract: Methods to treat spinal cord injury using &agr;d monoclonal antibodies are disclosed.
    Type: Grant
    Filed: October 13, 2000
    Date of Patent: August 13, 2002
    Assignee: ICOS Corporation
    Inventors: W. Michael Gallatin, Monica Van der Vieren
  • NOVEL HUMAN BETA2 INTEGRIN ALPHA SUBUNIT
    Publication number: 20020062008
    Abstract: Methods to inhibit inflammation and macrophage infiltration following spinal cord injury are disclosed along with methods to modulate TNF&agr; release from cells expressing &agr;d are disclosed.
    Type: Application
    Filed: July 8, 1999
    Publication date: May 23, 2002
    Inventors: W. MICHAEL GALLATIN, MONICA VAN DER VIEREN
  • Icam-related protein
    Publication number: 20010029293
    Abstract: DNA sequences encoding a novel human intercellular adhesion molecule polypeptide (designated “ICAM-R”) and variants thereof are disclosed along with methods and materials for production of the same by recombinant procedures. Binding molecules specific for ICAM-R and variants thereof are also disclosed as useful in both the isolation of ICAM-R from natural cellular sources and the modulation of ligand/receptor binding biological activities of ICAM-R.
    Type: Application
    Filed: January 3, 2001
    Publication date: October 11, 2001
    Applicant: ICOS Corporation
    Inventors: W. Michael Gallatin, Rosemay Vazeux